All In Biotech

Drug Trial Radar · NCT07374419

Atamparib in Patients With Advanced Solid Tumors

A Phase Ib/II Study of Atamparib in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

178

Planned (sponsor's estimate)

Start

Mar 18, 2026

Primary completion

Jul 31, 2028

Study completion Jan 31, 2029

Sponsor

Sponsor type
Industry
First posted
Jan 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-part, open-label, non-randomized phase Ib/II clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of atamparib, an investigational agent, in patients with advanced or metastatic non-small cell lung cancer (NSCLC) adenocarcinoma. The study comprises dose escalation (phase Ib) and expansion (phase II).

Conditions

  • NSCLC Adenocarcinoma
  • Solid Tumor

Interventions

  • atamparib escalation levelsDrug

    Bid, Oral, escalating at different dose levels

  • atamparib RP2DDrug

    Bid, oral, RP2D

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. RP2D and MTDTime frame: 28 days after the last dose
  2. Type, incidence and severity of adverse eventTime frame: until 28 days after the last dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Unit 3.53, 3rd Floor, No. 5, Lane 720 Cailun Road, Pilot Free Trade Zone, Shanghai, P.R.China

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.